Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

domatinostat in combination with avelumab

domatinostat tablets and avelumab infusion

Trial Locations (22)

Unknown

UZ Leuven, Leuven

Bordeaux Hôpital Saint Andre, Bordeaux

Hôpital Ambroise Paré - Boulogne-Billancourt, Boulogne-Billancourt

CHU Nantes - Hotel Dieu, Nantes

Hôpital Saint-Louis, Paris

Universitätsklinikum Köln, Cologne

Universitätsklinikum Dresden, Dresden

Helios Klinikum Erfurt, Erfurt

Universitätsklinikum Essen, Essen

Universitätsklinikum Heidelberg, Heidelberg

Universitätsklinikum Schleswig-Holstein Kiel, Kiel

Universitätsklinikum Leipzig, Leipzig

Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck

Technische Universität München, München

Universitätsklinikum Tübingen, Tübingen

Instituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari

Istituto Nazionale Tumori Fondazione G.Pascale, Naples

IOV - Istituto Oncologico Veneto IRCCS, Padua

Fondazione del Piemonte per l'Oncologia, Torino

Netherlands Cancer Institute Amsterdam, Amsterdam

Academic Hospital Maastricht, Maastricht

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
lead

4SC AG

INDUSTRY

NCT04393753 - Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 | Biotech Hunter | Biotech Hunter